Matches in SemOpenAlex for { <https://semopenalex.org/work/W3119973110> ?p ?o ?g. }
- W3119973110 endingPage "91" @default.
- W3119973110 startingPage "91" @default.
- W3119973110 abstract "Cyclosporin A (CsA) is a molecule with well-known immunosuppressive properties. As it also acts on the opening of mitochondrial permeability transition pore (mPTP), CsA has been evaluated for ischemic heart diseases (IHD). However, its distribution throughout the body and its physicochemical characteristics strongly limit the use of CsA for intravenous administration. In this context, nanoparticles (NPs) have emerged as an opportunity to circumvent the above-mentioned limitations. We have developed in our laboratory an innovative nanoformulation based on the covalent bond between squalene (Sq) and cyclosporin A to avoid burst release phenomena and increase drug loading. After a thorough characterization of the bioconjugate, we proceeded with a nanoprecipitation in aqueous medium in order to obtain SqCsA NPs of well-defined size. The SqCsA NPs were further characterized using dynamic light scattering (DLS), cryogenic transmission electron microscopy (cryoTEM), and high-performance liquid chromatography (HPLC), and their cytotoxicity was evaluated. As the goal is to employ them for IHD, we evaluated the cardioprotective capacity on two cardiac cell lines. A strong cardioprotective effect was observed on cardiomyoblasts subjected to experimental hypoxia/reoxygenation. Further research is needed in order to understand the mechanisms of action of SqCsA NPs in cells. This new formulation of CsA could pave the way for possible medical application." @default.
- W3119973110 created "2021-01-18" @default.
- W3119973110 creator A5003374394 @default.
- W3119973110 creator A5004408085 @default.
- W3119973110 creator A5013203026 @default.
- W3119973110 creator A5022503601 @default.
- W3119973110 creator A5024347721 @default.
- W3119973110 creator A5026148573 @default.
- W3119973110 creator A5038117884 @default.
- W3119973110 creator A5051295536 @default.
- W3119973110 creator A5060333382 @default.
- W3119973110 creator A5086065044 @default.
- W3119973110 creator A5089635381 @default.
- W3119973110 date "2021-01-12" @default.
- W3119973110 modified "2023-09-26" @default.
- W3119973110 title "New Nanoparticle Formulation for Cyclosporin A: In Vitro Assessment" @default.
- W3119973110 cites W1501910640 @default.
- W3119973110 cites W1525029829 @default.
- W3119973110 cites W1590085201 @default.
- W3119973110 cites W1983452367 @default.
- W3119973110 cites W1984957474 @default.
- W3119973110 cites W1986032553 @default.
- W3119973110 cites W1995662942 @default.
- W3119973110 cites W2000422002 @default.
- W3119973110 cites W2007482572 @default.
- W3119973110 cites W2027879036 @default.
- W3119973110 cites W2031298975 @default.
- W3119973110 cites W2034287144 @default.
- W3119973110 cites W2039898739 @default.
- W3119973110 cites W2043355876 @default.
- W3119973110 cites W2044806297 @default.
- W3119973110 cites W2048977380 @default.
- W3119973110 cites W2053706836 @default.
- W3119973110 cites W2062976933 @default.
- W3119973110 cites W2063645483 @default.
- W3119973110 cites W2066685510 @default.
- W3119973110 cites W2070637554 @default.
- W3119973110 cites W2091216349 @default.
- W3119973110 cites W2094657005 @default.
- W3119973110 cites W2097175042 @default.
- W3119973110 cites W2114611409 @default.
- W3119973110 cites W2125916785 @default.
- W3119973110 cites W2127072819 @default.
- W3119973110 cites W2129500787 @default.
- W3119973110 cites W2137544096 @default.
- W3119973110 cites W2143629227 @default.
- W3119973110 cites W2147640676 @default.
- W3119973110 cites W2153298328 @default.
- W3119973110 cites W2187976253 @default.
- W3119973110 cites W2200357463 @default.
- W3119973110 cites W2251914552 @default.
- W3119973110 cites W2288915657 @default.
- W3119973110 cites W2310629506 @default.
- W3119973110 cites W2331389349 @default.
- W3119973110 cites W2413455735 @default.
- W3119973110 cites W2415840490 @default.
- W3119973110 cites W2462747447 @default.
- W3119973110 cites W2519813884 @default.
- W3119973110 cites W2546810362 @default.
- W3119973110 cites W2555371277 @default.
- W3119973110 cites W2606547822 @default.
- W3119973110 cites W2607828023 @default.
- W3119973110 cites W2617427171 @default.
- W3119973110 cites W2791979595 @default.
- W3119973110 cites W2800675587 @default.
- W3119973110 cites W2809374624 @default.
- W3119973110 cites W2892874106 @default.
- W3119973110 cites W2903292093 @default.
- W3119973110 cites W2903834027 @default.
- W3119973110 cites W2911241431 @default.
- W3119973110 cites W2913941327 @default.
- W3119973110 cites W2921244657 @default.
- W3119973110 cites W2928131335 @default.
- W3119973110 cites W2930314817 @default.
- W3119973110 cites W2938047765 @default.
- W3119973110 cites W2947540934 @default.
- W3119973110 cites W2949821223 @default.
- W3119973110 cites W2954437208 @default.
- W3119973110 cites W2971296140 @default.
- W3119973110 cites W2996218325 @default.
- W3119973110 cites W3018463525 @default.
- W3119973110 cites W3045726767 @default.
- W3119973110 cites W4249074344 @default.
- W3119973110 doi "https://doi.org/10.3390/pharmaceutics13010091" @default.
- W3119973110 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7828155" @default.
- W3119973110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33445646" @default.
- W3119973110 hasPublicationYear "2021" @default.
- W3119973110 type Work @default.
- W3119973110 sameAs 3119973110 @default.
- W3119973110 citedByCount "5" @default.
- W3119973110 countsByYear W31199731102021 @default.
- W3119973110 countsByYear W31199731102022 @default.
- W3119973110 countsByYear W31199731102023 @default.
- W3119973110 crossrefType "journal-article" @default.
- W3119973110 hasAuthorship W3119973110A5003374394 @default.
- W3119973110 hasAuthorship W3119973110A5004408085 @default.
- W3119973110 hasAuthorship W3119973110A5013203026 @default.
- W3119973110 hasAuthorship W3119973110A5022503601 @default.